Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors

References

• Albertí J, Martinet A, Sentellas S, Salvà M. (2010). Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 38:1202–10.
   PubMed Web of Science ®Google Scholar
• Atack JR, Yu QS, Soncrant TT, et al. (1989). Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases. J Pharmacol Exp Ther 249:194–202.
   PubMed Web of Science ®Google Scholar
• Bencharit S, Morton CL, Hyatt JL, et al. (2003). Crystal structure of human carboxylesterase 1 complexed with the Alzheimer’s drug tacrine: from binding promiscuity to selective inhibition. Chem Biol 10:341–9.
   PubMed Web of Science ®Google Scholar
• Berry LM, Wollenberg L, Zhao Z. (2009). Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett 3:70–7.
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32.
   PubMed Web of Science ®Google Scholar
• Camps J, Marsillach J, Joven J. (2009). The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 46:83–106.
   PubMed Web of Science ®Google Scholar
• Fukami T, Yokoi T. (2012). The emerging role of human esterases. Drug Metab Pharmacokinet 27:466–77.
   PubMed Web of Science ®Google Scholar
• Gonzalvo MC, Gil F, Hernández AF, et al. (1997). Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 105:169–79.
   PubMed Web of Science ®Google Scholar
• Holmes RS, Wright MW, Laulederkind SJ, et al. (2010). Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. Mamm Genome 21:427–41.
   PubMed Web of Science ®Google Scholar
• Humerickhouse R, Lohrbach K, Li L, et al. (2000). Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189–92.
   PubMed Web of Science ®Google Scholar
• Jbilo O, Bartels CF, Chatonnet A, et al. (1994). Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 32:1445–57.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Fukami T, Higuchi R, et al. (2012). Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. Biochem Pharmacol 84:1196–206.
   PubMed Web of Science ®Google Scholar
• Kuo CL, La Du BN. (1998). Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. Drug Metab Dispos 26:653–60.
   PubMed Web of Science ®Google Scholar
• Laizure SC, Herring V, Hu Z, et al. (2013). The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 33:210–22.
   PubMed Web of Science ®Google Scholar
• Li B, Sedlacek M, Manoharan I, et al. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84.
   PubMed Web of Science ®Google Scholar
• Liston DR, Nielsen JA, Villalobos A, et al. (2004). Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur J Pharmacol 486:9–17.
   PubMed Web of Science ®Google Scholar
• Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. (2001). Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444–9.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Usuki E, Yerino P, Parkinson A. (2008). In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450. In: Rodrigues AD, ed. Drug–drug interactions. 2nd ed. New York: Informa Healthcare, 231--358.
   Google Scholar
• Proctor NJ, Tucker GT, Rostami-Hodjegan A. (2004). Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151–78.
   PubMed Web of Science ®Google Scholar
• Reiner E, Pavković E, Radić Z, Simeon V. (1993). Differentiation of esterases reacting with organophosphorus compounds. Chem Biol Interact 87:77–83.
   PubMed Web of Science ®Google Scholar
• Sato Y, Miyashita A, Iwatsubo T, Usui T. (2012). Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos 40:902–6.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fukami T, Nakajima M, Yokoi T. (2014). Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos 42:1103–9.
   PubMed Web of Science ®Google Scholar
• Tang M, Mukundan M, Yang J, et al. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467–76.
   PubMed Web of Science ®Google Scholar
• Wang J, Williams ET, Bourgea J, et al. (2011). Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2. Drug Metab Dispos 39:1329–33.
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang W, Ma MK, McLeod HL. (2002). Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605–11.
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Wang X, Gawronski BE, et al. (2013). Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 344:665–72.
   PubMed Web of Science ®Google Scholar